Does TADALAFIL Cause Pulmonary arterial hypertension? 680 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 680 reports of Pulmonary arterial hypertension have been filed in association with TADALAFIL (Esokalli Testosterone Booster Oral Dissolving Film). This represents 2.2% of all adverse event reports for TADALAFIL.
680
Reports of Pulmonary arterial hypertension with TADALAFIL
2.2%
of all TADALAFIL reports
267
Deaths
396
Hospitalizations
How Dangerous Is Pulmonary arterial hypertension From TADALAFIL?
Of the 680 reports, 267 (39.3%) resulted in death, 396 (58.2%) required hospitalization, and 33 (4.9%) were considered life-threatening.
Is Pulmonary arterial hypertension Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TADALAFIL. However, 680 reports have been filed with the FAERS database.
What Other Side Effects Does TADALAFIL Cause?
Headache (3,196)
Drug ineffective (2,943)
Dyspnoea (2,881)
Death (1,917)
Diarrhoea (1,667)
Dizziness (1,374)
Nausea (1,368)
Asthenia (1,230)
Fatigue (1,135)
Hypertension (1,044)
What Other Drugs Cause Pulmonary arterial hypertension?
TREPROSTINIL (3,240)
MACITENTAN (2,390)
AMBRISENTAN (1,965)
SELEXIPAG (1,387)
EPOPROSTENOL (1,055)
BOSENTAN (778)
SILDENAFIL (487)
RIOCIGUAT (436)
ILOPROST (284)
BOSENTAN\BOSENTAN (245)
Which TADALAFIL Alternatives Have Lower Pulmonary arterial hypertension Risk?
TADALAFIL vs TAFAMIDIS
TADALAFIL vs TAFAMIDIS MEGLUMINE
TADALAFIL vs TAFASITAMAB
TADALAFIL vs TAFASITAMAB-CXIX
TADALAFIL vs TAFINLAR